LA JOLLA, Calif., Feb. 20, 2008 (PRIME NEWSWIRE) -- Duska Therapeutics, Inc. (OTC BB:DSKA.OB - News), a biopharmaceutical company developing diagnostic and therapeutic products based on adenosine 5'-triphosphate (ATP) and P2 receptor-related technologies, announced today that James S. Kuo, M.D., M.B.A., Chairman and Chief Executive Officer, will present at the Winter Global Equities Conference on Monday, February 25, 2008 at 11:00 AM Pacific Standard Time. The conference will be held at The Palms Hotel in Las Vegas, Nevada.

About Duska Therapeutics, Inc.

Duska Therapeutics focuses on the development of therapeutic and diagnostic products related to adenosine 5'-triphosphate (ATP), and cell-surface P2 receptors (P2R). Duska owns or has exclusive license rights to a number of proprietary diagnostic and therapeutic applications, four of which are currently in various stages of development in the fields of cardiac arrhythmias, male infertility, chronic obstructive pulmonary disorders and cough, and glaucoma. For more information, visit Duska's website at http://www.duskatherapeutics.com.

Forward-looking statements

This press release may contain forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, The forward-looking statements are based on current expectations, estimates and projections made by management. Duska intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as ``anticipates,'' ``expects,'' ``intends,'' ``plans,'' ``believes'' ''seeks,`` ''estimates,`` or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Duska are forward-looking statements. Additional uncertainties and risks are described in Duska's most recently filed SEC documents, such as its most recent annual report on Form 10-KSB, all quarterly reports on Form 10-QSB and any current reports on Form 8-K filed since the date of the last Form 10-KSB. Copies of these filings are available through the SEC website at http://www.sec.gov. All forward-looking statements are based upon information available to Duska on the date hereof. Duska undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

          Duska Therapeutics, Inc.
          James S. Kuo, M.D., M.B.A., Chairman and CEO
          858.551.5700
          Fax: 858.551.5704
          kuoj@duskatherapeutics.com
          470 Nautilus Street, Suite 300
          La Jolla, CA 92037